Lineage Cell Therapeutics LCTX
$ 0.6
-6.58%
Quarterly report 2024-Q3
added 11-14-2024
Lineage Cell Therapeutics Cash Flow 2011-2024 | LCTX
Annual Cash Flow Lineage Cell Therapeutics
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-28.6 M | 1.06 M | -23.6 M | -19.8 M | -31.9 M | -30.9 M | -30.5 M | -42.3 M | -44.5 M | - | -29.5 M | -19.7 M | -13.6 M |
Depreciation & Amortization |
562 K | 582 K | 663 K | 823 K | 1 M | 1.08 M | 947 K | 1.18 M | 1.08 M | 1.05 M | 657 K | 386 K | 373 K |
Accounts Payables |
2.05 M | 2.39 M | 3.54 M | 2.61 M | 2.43 M | 2.36 M | 938 K | 1.59 M | 2.8 M | 2.3 M | 3.89 M | 1.17 M | - |
Accounts Receivables |
745 K | 297 K | 50.6 M | - | - | 51 K | 139 K | 344 K | 754 K | 549 K | 576 K | 404 K | - |
Total Inventories |
- | - | - | - | - | - | - | - | - | 266 K | 179 K | 55.3 K | 51.2 K |
All numbers in USD currency
Quarterly Cash Flow Lineage Cell Therapeutics
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | -5.78 M | - | - | - | -11.2 M | - | 9.36 M | 14.8 M | 21.9 M | - | -17.7 M | -12.8 M | -7.42 M | - | -14.1 M | -9.26 M | -5.03 M | - | -26.4 M | -19 M | -9.31 M | - | -25.1 M | -17.7 M | -10.3 M | - | -24.8 M | -17.2 M | -8.1 M | - | -33.5 M | -24.6 M | - | - | - | - | - | - | - | - | -10.4 M | - | - | - | -7.02 M | - | -14.7 M | -9.67 M | -5.72 M | - | -9.75 M | -6.15 M | -3.36 M |
Depreciation & Amortization |
141 K | 142 K | 153 K | - | 143 K | 138 K | 138 K | - | 145 M | 146 M | 150 K | - | 504 K | 338 K | 174 K | - | 200 K | 210 K | 212 K | - | 253 K | 244 K | 269 K | - | 254 K | 279 K | 281 K | - | 249 K | 205 K | 216 K | - | 996 K | 748 K | 429 K | - | 776 K | 512 K | 263 K | - | 794 K | 523 K | 257 K | - | 420 K | 113 K | 113 K | - | 284 K | 88.7 K | 88.7 K | - | 261 K | 128 K | 65.2 K |
Accounts Payables |
1.6 M | 2.39 M | 2.21 M | 2.05 M | 2.43 M | 2.19 M | 3 M | 2.39 M | 2.86 M | 2.59 M | 2.96 M | 3.54 M | 3.46 M | 2.72 M | 2.8 M | 2.61 M | 2.61 M | 2.61 M | 2.61 M | 2.43 M | 2.43 M | 2.43 M | 2.43 M | 2.36 M | 2.36 M | 2.36 M | 2.36 M | 938 K | 938 K | 938 K | 938 K | 1.59 M | 1.59 M | 1.59 M | 1.59 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 3.43 M | 3.89 M | 3.89 M | 3.89 M | 1.17 M | 1.17 M | 1.17 M | 1.17 M | 1.12 M | 1.12 M | 1.12 M | - |
Accounts Receivables |
405 K | 235 K | 77 K | 745 K | 432 K | 406 K | 173 K | 297 K | 435 K | 532 K | 323 K | 50.6 M | 2.12 M | - | - | 242 K | 242 K | - | - | 44 K | - | - | - | 51 K | - | - | - | 139 K | - | - | - | 344 K | - | - | - | 754 K | 664 K | 545 K | 606 K | 549 K | 549 K | 549 K | 549 K | 576 K | 576 K | 576 K | 576 K | 395 K | 395 K | 395 K | 395 K | 353 K | 353 K | 353 K | - |
Total Inventories |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 K | 260 K | 297 K | 299 K | 266 K | 266 K | 266 K | 266 K | 179 K | 179 K | 179 K | 179 K | 55.3 K | 55.3 K | 55.3 K | 55.3 K | 51.2 K | 51.2 K | 51.2 K | 51.2 K |
All numbers in USD currency